<DOC>
	<DOC>NCT03092154</DOC>
	<brief_summary>The use of lipid lowering agents in patients with idiopathic inflammatory myopathies is controversial. Therefore, the aim of the present study is to assess clinically and laboratory the impact of lipid-lowering agents in this population.</brief_summary>
	<brief_title>Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis</brief_title>
	<detailed_description>Impact of the lipid lowering agents on patients with dermatomyositis and polymyositis.</detailed_description>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<criteria>fullfill all criteria of Bohan and Peter (1975) dyslipidemia age&gt; 18 years prednisone ≤ 0.25 mg/kg/day (or ≤ 15mg/ ay) in the last three months without changing nutritional habits in the last three months, and during the study period no change of lifestyle in the last three months, and during the study period Patients with: disease relapsing overlapping myositis neoplasia associated myositis diabetes mellitus current and/or chronic infections patients undergoing major surgery within six months prior to the study pregnant patients previous use of lipidlowering agents in the last 6 months in the use of cyclosporin, erythromycin, clarithromycin, fibrates, niacin, azole antifungals, cimetidine, diltiazem active liver disease or persistent elevations of hepatic enzymes, with no apparent cause, exceeding three times the upper limit of normality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>